Lonza collaborates on commercial supply manufacturing for anti-coagulation antidote 05-Feb-2019 By Maggie Lynch Portola and Lonza will collaborate on commercial supply the API for the former’s anti-coagulation antidote at Lonza’s facilities.
Portola navigates manufacturing woes to gain US approval 08-Jan-2019 By Ben Hargreaves The company’s anticoagulant reversal treatment received a complete response letter from the FDA in 2016 but will be made available today after its approval.